Bisphosphonates in the prevention and treatment of metastatic bone disease

Breast

Volumn 8, Issue 2, 1999, Pages 57-62

  Coleman, R E ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; CYTOTOXIC AGENT; HORMONE; PAMIDRONIC ACID;

BEAM THERAPY; BONE CELL; BONE METABOLISM; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CELL INTERACTION; COMPLICATION; DRUG TOLERABILITY; FEMALE; HORMONAL THERAPY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC DISORDER; NONHUMAN; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; SYMPTOM; TUMOR CELL;

EID: 0032806116     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(99)90000-0     Document Type: Review

References (33)

1. Mundy G R. Mechanisms of bone metastasis. Cancer 80 (suppl 8) 1997; 1547-1556.
2. Urwin G H, Percival R C, Harris S, Kanis J. Generalised increase in bone resorption in carcinoma of the prostate. Br J Urol 1985; 57: 721.
3. Coleman R E. Skeletal complications of malignancy. Cancer (suppl) 1997 (8)8: 1588-1594.
4. Rogers M J, Watts D J, Russell R G G. Overview of bisphosphonates. Cancer (suppl) 1997; 80(8): 1652-1660.
5. Hughes D E, Wright K R, Uy H L, Sasaki A, Yoneda T, Roodman G D et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995 (10): 1478-1487.
6. Rogers M J, Xiong X, Ji X, Monkkonen J, Russell R G G, Blackburn G M et al. Inhibition of growth of dictyostelium discoideum amoeboe by bisphosphonates is dependent on cellular uptake. Pharmacol Res 1997 (14): 625-630.
7. Shipman C M, Rogers M J, Apperley J F, Russell G G, Croucher P I. Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity. Br J Haematol 1997 (98): 665-672.
8. Hiraga T, Williams P J, Kawakatsu H, Mundy G R, Yoneda T. The bisphosphonate ibandronate increases apoptosis of metastatic breast cancer cells as well as osteoclasts. Proc Amer Soc Bone Miner Res S192; 1998: A1183.
9. Purohit O P, Radstone C R, Anthony C et al. A randomised doubleblind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br J Cancer 1995 (72): 1289-1293.
10. Elomaa I, Blomqvist C, Grohn P, Porkka L, Kairento A L, Selander K et al. Long-term controlled trial of bisphosphonate in patients with osteolytic bone metastases. Lancet 1983 (1): 146-149.
11. Vinholes J J, Purohit O P, Abbey M E, Eastell R, Coleman R E. Relationships between biochemical and symptomatic response in a double-blind trial of pamidronate for metastatic bone disease. Ann Oncol 1997 (8): 1243-1250.
12. Coleman R E, Woll P J, Miles M, Scrivener W, Rubens R D. Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1.1-biphosphonate (APD). Br J of Cancer 1988 (56): 465-469.
13. Paterson A H G, Powles T J, Kanis JA, McCloskey E, Hanson J, Ashley S. Double blind controlled trial of clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993 (11): 59-65.
14. van Holten-Verzantvoort A T, Bijvoet O L M, Cleton F J et al. Reduced morbidity from skeletal metastases in breast cancer patients during long term bisphosphonate (APD) treatment. Lancet 1987 (ii): 983-985.
15. Conte P F, Mauriac L, Calabresi F, Santos R et al. Delay in progression of bone metastases treated with intravenous pamidronate: Results from a multicentre randomised controlled trial. J Clin Oncol 1996 (14): 2552-2559.
16. Hultborn R, Ryden S, Gunderson S, Holmberg E, Wallgren U-B. Efficacy of pamidronate on skeletal complications from breast cancer metastases. A randomised prospective double blind placebo controlled trial. Acta Oncologica (suppl 5) 1996 (35): 73-74.
17. Hortobagyi G N, Theriault R L, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. New Engl J Med 1996 (335): 1785-1791.
18. TM) infusions. ASCO Proceedings 1997 (16): 152a.
19. Hortobagyi G N, Theriault R L, Lipton A, Porter L, Blayney D et al. Long term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 1998 (16): 2038-2044.
20. Body J-J, Coleman R E, Piccart M. Use of bisphosphonates in cancer patients. Cancer Treatment Review 1996 (22): 265-287.
21. Vinholes J J, Purohit O P, Abbey M E, Eastell R, Coleman R E. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcaemia of malignancy. J Clin Oncol 1997 (15): 131-138.
22. Purohit O P, Anthony C, Radstone C R, Owen J, Coleman R E. High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer 1994 (70): 554-558.
23. Body J J, Burckhardt P, Delmas P D et al. Current use of bisphosphonates in oncology. J Clin Oncol 1998 (16): 3890-3899.
24. Coleman R E, Purohit O P, Vinholes J J, Zekri J. High dose pamidronate - Clinical and biochemical effects in metastatic bone disease. Cancer 1997 80 (8): 1686-1690.
25. Vinholes J J, Guo C-Y, Purohit O P, Eastell R, Coleman R E. Metabolic effects of pamidronate in patients with metastatic bone disease. Br J Cancer 1996 (73): 1089-1095.
26. Sasaki A, Boyce B F, Story B et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 1995 (55): 3551-3557.
27. Kanis J A, Powles T, Paterson A H G et al. Clodronate decreases the frequency of skeletal metastases with breast cancer. Bone 1996 (19): 663-667.
28. Powles T J, Paterson A H G, Nevantaus A et al. Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer. ASCO Proceedings 1998 (17): 468a.
29. Diel I, Solomayer E-F, Costa S J et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998 (339): 357-363.
30. Saarto S, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss which is reduced by clodronate: A randomised study in premenopausal patients. J Clin Oncol 1997 (15): 1341-1347.
31. Coleman R E, Rubens R D. The clinical course of bone metastases from breast cancer. Br J Cancer 1987 (55): 61-66.
32. Coleman R E, Smith P, Rubens R D. Clinical course and prognostic factors following recurrence from breast cancer. Br J Cancer 1998 (17): 336-340.
33. British Association of Surgical Oncology. BASO guidelines for the management of metastatic bone disease. Eur J Surg Oncol, in press, 1999.